Pharma Tech

AstraZeneca to invest $2bn in Summit for ADC combination therapies

Sep 29, 2026, 9:34 AM

Read Full Article → AstraZeneca to invest $2bn in Summit for ADC combination therapies

Translate article text

Choose a language and wait for the translated text.

AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and ADCs across multiple tumour types.